TP53 and acute myeloid leukemia: The combination of AZA with venetoclax (VEN) has achieved complete response (CR)/CR with incomplete count recovery (CRi) rates of 70% in patients with adverse-risk cytogenetic AML without TP53 mutations, as well as durable remission (18.4 months) and improved OS (23.4 months) [91].